AnPac Bio-Medical Science Co., Ltd (ANPC)

Etorro trading 970x250
AnPac Bio-Medical Science Co., Ltd (ANPC) Logo

About AnPac Bio-Medical Science Co., Ltd

Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People’s Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People’s Republic of China. Address: 801 Bixing Street, Lishui, China, 323006

AnPac Bio-Medical Science Co., Ltd News and around…

Latest news about AnPac Bio-Medical Science Co., Ltd (ANPC) common stock and company :

Second-, Third-Degree Relatives of Colon Cancer Patients at Risk of Developing the Ailment
13 Oct, 2021 FinancialContent
AnPac Bio-Medical Science Co. Ltd. Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection
13 Oct, 2021 Yahoo! Finance

Blood and genomic testing are becoming preferable means of early cancer screening and detection Leaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive, and Guardant AnPac Bio-Medical’s testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test database) that detect up to 26 different types of cancer One of the few companies offering multi-cancer tests for risk assessment and actually c

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection
12 Oct, 2021 FinancialContent
BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment
11 Oct, 2021 FinancialContent
AnPac Bio-Medical Science Co. Ltd. Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer
04 Oct, 2021 Yahoo! Finance

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection has reached a significant milestone and positive result in its general population, cancer-risk assessment tests, and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer, and disease cases. According to the announcements, those cases include 22 identified types of canc

Researchers Find Colorectal Cancer Cases Are Higher in Minorities
04 Oct, 2021 FinancialContent
BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer
04 Oct, 2021 FinancialContent
AnPac Bio Study Shows Strong Correlation between CDA Score and Risk of Cancer and Diseases
04 Oct, 2021 Yahoo! Finance

Large Population Screening Study Reached Key Milestone with Over 2,000 Confirmed CasesPHILADELPHIA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq:ANPC, “AnPac Bio,” the “Company” or “we”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it has achieved a significant milestone and positive result in its general population cancer risk assessment tests and subsequent follow-up stu

AnPac Bio-Medical Science Co. Ltd. First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%
01 Oct, 2021 Yahoo! Finance

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released its unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated $1.4 million, an increase of 128.5% compared to the same period in 2020; gross profit margin of 61.4%, an increase of 16.1 percentage points from the same six-month period in 2020; and the average selling price of CDA-based tests b

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%
01 Oct, 2021 FinancialContent
AnPac Bio 2021 First Half Revenue Up 128.5% with Non-GAAP Loss Reduced by 18.3%
01 Oct, 2021 Yahoo! Finance

PHILADELPHIA, Oct. 01, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the six months ended June 30, 2021. Financial highlights: Total revenues were approximately RMB9.3 million (US$1.4 million) for the six months ended June 30, 2021, representing an increase of 128.5% from approximately RMB4.1 million for th

AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Listed Securities Deficiency
30 Sep, 2021 FinancialContent
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) 10 Years in the Making: Innovation Leads to Multi (Pan)-Cancer Screening
28 Sep, 2021 FinancialContent
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leading the Way in Early Cancer Detection Space
27 Sep, 2021 FinancialContent
BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types
24 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's After-Market Session
22 Sep, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 21.54% to $25.1 during Wednesday's after-market session. ...

AnPac Bio-Medical Science Co. Ltd. Receives College Of American Pathologists Accreditation For US Laboratory
22 Sep, 2021 Yahoo! Finance

AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021 Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening Company’s ownership percentage in subsidiary AnPai (Shanghai) Healthcare Management Consultant Co. Ltd. has increased from 20% to 60%, following rigorous regulatory a

Six Common Types of Brain Tumors
22 Sep, 2021 FinancialContent
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory
22 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
21 Sep, 2021 FinancialContent

Gainers Viridian Therapeutics (NASDAQ:VRDN) shares rose 18.05% to $12.62 during Tuesday's pre-market session. The ...

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline
14 Sep, 2021 FinancialContent
New Prototype Device Eliminates Radiation Exposure from Breast Cancer Screening
14 Sep, 2021 FinancialContent
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for National Medical Products Administration Registration of Early-Warning Cancer Technology with a Record 11 Tumor Types Under Formal Medical D
13 Sep, 2021 FinancialContent
AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment
08 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Tuesday's After-Market Session
07 Sep, 2021 FinancialContent

Gainers Cellectar Biosciences (NASDAQ:CLRB) shares increased by 3.84% to $1.08 during Tuesday's after-market session. This security ...

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase In Subsidiary Holding
07 Sep, 2021 FinancialContent

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai ...

12 Health Care Stocks Moving In Friday's After-Market Session
03 Sep, 2021 FinancialContent

Gainers Enveric Biosciences (NASDAQ:ENVB) shares rose 7.22% to $2.82 during Friday's after-market session. Today's trading volume ...

AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%
03 Sep, 2021 FinancialContent
Experts Recommend That Colorectal Cancer Screening Start at Age 45
31 Aug, 2021 FinancialContent
BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CLIA Laboratory Receives Accreditation from the College of American Pathologists
30 Aug, 2021 FinancialContent

AnPac Bio-Medical Science Co., Ltd (ANPC) is a NASDAQ Common Stock listed in , ,

970x250